A Phase 1/2 Study of PF-02341066, an Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-Met, in Children with Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma
A study of children with relapsed or refractory solid tumors and large cell lymphoma using study drug, PF-02341066 for treatment
Sponsor: Children's Oncology Group
Enrolling: Male and Female Patients
IRB Number: AAAE7196
U.S. Govt. ID: NCT00939770
Contact: Julia Glade Bender: 212-305-5808 / jg589@columbia.edu
Additional Study Information: The purpose of this study is to examine the effectiveness and tolerability of a study drug called PF-02341066. Additional goals of this study are to learn how the body handles the study drug as well as determine whether or not PF-02341066 is a beneficial treatment for your tumor This study is for children with a recurrent or progressive tumor or lymphoma that cannot be cured by any known standard treatment.
This study is closed
Investigator
Julia Glade Bender, MD
Do You Qualify?
Have your child recovered from prior chemotherapy, immunotherapy, or radiotherapy? Yes No
Is you child taking any investigational drugs? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Julia Glade Bender
jg589@columbia.edu
212-305-5808
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE